An Important Step Forward for Biosimilars in Cancer Treatment

JAMA Oncol. 2017 Jul 1;3(7):989-990. doi: 10.1001/jamaoncol.2016.6789.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Comparative Study
  • Equivalence Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Biosimilar Pharmaceuticals / administration & dosage*
  • Biosimilar Pharmaceuticals / adverse effects
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Disease Progression
  • Double-Blind Method
  • Female
  • Humans
  • Intention to Treat Analysis
  • Middle Aged
  • Receptor, ErbB-2 / metabolism*
  • Survival Analysis
  • Taxoids / administration & dosage*
  • Taxoids / adverse effects
  • Trastuzumab / administration & dosage*
  • Trastuzumab / adverse effects
  • Treatment Outcome

Substances

  • Biosimilar Pharmaceuticals
  • Taxoids
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab